Exploration of Cardiology

From: Comparative analysis of cardiometabolic parameters in patients with coronary heart disease with and without non-alcoholic fatty liver disease

Table 5. Lipid and glycemic profiles in both groups

Indicator	Group I (n = 61)	Group II (n = 24)	p
Total cholesterol, mg/dL	192 ± 6.5	163.6 ± 13.7	0.0091*
LDL, mg/dL	102.2 ± 7.4	93.3 ± 15.7	0.2482
HDL, mg/dL	42.5 ± 8.6	45.2 ± 9.3	0.4727
VLDL, mg/dL	44.7 ± 5.4	22.6 ± 11.2	< 0.0001*
Triglycerides, mg/dL	224.4 ± 36.2	112.7 ± 21.6	0.0003*
Fasting glucose, mmol/L	6.0	5.5	0.4214
HbA1С, %	7.9	7.0	0.7477
Insulin, µIU/mL	15.4	4.9	0.0035*
HOMA-IR	3.9	1.9	0.1466

Return to article view

*: p < 0.05. HbA1С: glycated hemoglobin; HDL: high-density lipoprotein; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; LDL: low-density lipoprotein; VLDL: very low-density lipoprotein

Declarations

Author contributions

DBY: Conceptualization, Investigation, Writing—original draft. RBA: Conceptualization, Writing—review & editing, Supervision. UIN: Investigation, Writing—review & editing, Supervision. ABS: Writing—review & editing, Supervision. SA: Conceptualization, Investigation. NN: Writing—review & editing, Supervision. SMS: Conceptualization, Writing—original draft. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study was approved by the Republican Specialized Scientific and Practical Medical Center of Cardiology Ethics Committee (approval number № 2) and complies with the Declaration of Helsinki.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Informed consent to publication was obtained from relevant participants.

Availability of data and materials

The data for this study could be available from the corresponding authors upon reasonable request.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Eriksen CU, Rotar O, Toft U, Jørgensen T. What is the effectiveness of systematic population-level screening programmes for reducing the burden of cardiovascular diseases [Internet]? Copenhagen: WHO Regional Office for Europe; c2021 [cited 2025 May 25]. Available from: https://www.who.int/europe/publications/i/item/9789289055376

Adhikary D, Barman S, Ranjan R, Stone H. A Systematic Review of Major Cardiovascular Risk Factors: A Growing Global Health Concern. Cureus. 2022;14:e30119. [DOI] [PubMed] [PMC]

Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015;239:192–202. [DOI] [PubMed]

Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65:589–600. [DOI] [PubMed]

Wójcik-Cichy K, Koślińska-Berkan E, Piekarska A. The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. Clin Exp Hepatol. 2018;4:1–6. [DOI] [PubMed] [PMC]

Cazac GD, Lăcătușu CM, Mihai C, Grigorescu ED, Onofriescu A, Mihai BM. New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis. Life (Basel). 2022;12:1189. [DOI] [PubMed] [PMC]

Kim SH, Park HY, Lee HS, Jung KS, Lee MH, Jhee JH, et al. Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity. Sci Rep. 2020;10:1025. [DOI] [PubMed] [PMC]

Ikezaki H, Nakashima R, Matsumoto Y, Ohta A, Yamasaki S, Hiramine S, et al. Impact of NAFLD-related SNPs on the carotid atherosclerosis development; a five-year prospective observational study. Atheroscler Plus. 2024;59:10–7. [DOI] [PubMed] [PMC]

Trovato FM, Martines GF, Catalano D, Musumeci G, Pirri C, Trovato GM. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J Cardiol. 2016;221:275–9. [DOI] [PubMed]

10.

Fracanzani AL, Pisano G, Consonni D, Tiraboschi S, Baragetti A, Bertelli C, et al. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS One. 2016;11:e0162473. [DOI] [PubMed] [PMC]

11.

Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:948–63. [DOI] [PubMed]

12.

Zhou YY, Zhou XD, Wu SJ, Fan DH, Van Poucke S, Chen YP, et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatol Commun. 2018;2:376–92. [DOI] [PubMed] [PMC]